Can you get peptides through telehealth? Yes, legally, when the peptide is an FDA-approved drug or one a pharmacy may lawfully compound, the prescriber is licensed in your state and the pharmacy is licensed to ship there. The video call is rarely the legal problem. The molecule and the pharmacy usually are.
Here is the argument of this piece. Most coverage of peptide telehealth frames it as a question about telemedicine law, a fifty-state patchwork that makes online prescribing risky. That framing points at the wrong layer. Federal law does not ban prescribing a non-controlled drug over video, and most peptides are not controlled substances. The state patchwork is real, but it mostly governs who may prescribe and who may ship, not which molecule is legal. The question that decides whether a telehealth peptide offer is lawful is the one the marketing spends the least time on: is the drug approved, and if it is compounded, is the ingredient one a pharmacy is allowed to use? In 2026 the answer for the most popular research peptides did not change.
Nothing below is legal or medical advice, and nothing here recommends a provider, a pharmacy or a compound. This page reports what the statutes, the Federal Register and the regulators say, with the primary document linked for each claim. For where each compound stands on the FDA compounding lists, the Ozemback peptide status tracker keeps a dated row per compound. BPC-157 and TB-500, the two names most often attached to telehealth peptide offers, each have a reference page with their legal history laid out by date, and the earlier piece on the 503A bulks list explains the compounding rules in full.
Is it legal to prescribe peptides over telehealth?
Federal law has no general rule against prescribing a drug after a video visit. The one federal in-person requirement, added to the Controlled Substances Act by the Ryan Haight Act and codified at 21 U.S.C. 829(e), applies only to controlled substances dispensed by means of the Internet: for those, a valid prescription requires at least one in-person medical evaluation, subject to exceptions. BPC-157, TB-500, MOTS-c, sermorelin and tesamorelin do not appear on the DEA's alphabetical list of controlled substances, so that rule does not reach them. Testosterone does appear, in Schedule III, and that distinction matters because many clinics that sell peptides online also sell hormone therapy. A peptide-only telehealth practice and a testosterone telehealth practice sit under two different federal regimes, even when they share a website.
What happens to telehealth prescribing after December 31, 2026?
For controlled substances, the date to watch is 31 December 2026. On 31 December 2025 the DEA and HHS published in the Federal Register a fourth temporary extension of the COVID-era telemedicine flexibilities, letting registered practitioners prescribe controlled medications without a prior in-person visit through 31 December 2026. A permanent rule had not replaced the flexibilities when that notice was published. If they lapse without one, the in-person requirement of 21 U.S.C. 829(e) is the default again for controlled substances, which is our reading of the statute rather than a DEA statement. For a telehealth testosterone prescription that is a live question this winter. For BPC-157 or sermorelin it is not, because the DEA rule never covered them, and an article that ties the two together is mixing up two separate laws.
Which peptides can a telehealth doctor legally prescribe?
Three categories decide it, and the telehealth channel does not change any of them. FDA-approved peptide drugs, such as semaglutide, tirzepatide and tesamorelin, can be prescribed by any licensed prescriber and dispensed by any licensed pharmacy, online or not. Compounded drugs are governed by section 503A of the Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a: a drug must be compounded for an identified individual patient on a valid prescription, and each bulk ingredient must meet a USP or National Formulary monograph, be a component of an approved drug, or appear on a list FDA issues by regulation. Peptides that fit none of those routes cannot be compounded under 503A, whatever the prescriber writes. A telehealth prescription is valid paper. It does not make an ineligible ingredient eligible.
| Type of peptide | Examples | What a telehealth prescription can lawfully lead to |
|---|---|---|
| FDA-approved drug | Semaglutide, tirzepatide, tesamorelin | Dispensing of the approved product by a licensed pharmacy |
| Compoundable under 503A | Ingredients with a USP/NF monograph, in an approved drug, or on the 503A list | A compounded preparation for that named patient |
| Reviewed by the July 2026 panel, not listed | BPC-157, KPV, TB-500, MOTS-c | No lawful 503A compounding route as of 28 October 2026 |
| Controlled substance | Testosterone (Schedule III) | Prescription under DEA rules; flexibilities end 31 Dec 2026 |
The third row is where most telehealth peptide marketing lives. On 16 April 2026 FDA published a Federal Register notice convening its Pharmacy Compounding Advisory Committee and opening a docket on substances nominated for the 503A list, including BPC-157, KPV, TB-500 and MOTS-c. On 23 July 2026 the committee voted 8 to 6, with one abstention, in favour of listing BPC-157, against the advice of FDA staff. A committee vote is a recommendation, not a rule. A search of the Federal Register on 28 October 2026 returns that April notice and no proposed or final rule adding any of these peptides to the list. Until one is published and takes effect, the vote does not change what a 503A pharmacy may compound, and a telehealth visit does not either.
Do telehealth doctors need a license in my state?
Generally yes, and here the state patchwork is real. Medical licensure is state law, and states treat the patient's location as the place where care happens. The Interstate Medical Licensure Compact speeds up multi-state licensing: as of 30 September 2026 its commission listed 44 member states and two US territories, with Alaska, New Mexico and Rhode Island still implementing. The compact is an expedited route to a license in each state, not a national license. Some states add their own path. Florida's telehealth statute, section 456.47, lets an out-of-state provider treat patients located in Florida by registering with the relevant board instead of holding a full Florida license, provided the home-state license is active and unencumbered with no discipline in the prior five years. The same statute bars using telehealth to prescribe Schedule II drugs outside psychiatric, hospital, hospice and nursing-home care.
Can an out-of-state pharmacy ship peptides to me?
Only if it is licensed or registered to ship into your state, and that requirement is the most concrete check a reader can see. Florida's section 465.0156 is a representative example: a nonresident pharmacy that mails dispensed drugs to Florida patients must register with the Florida Board of Pharmacy, hold a valid license in the state where it dispenses, keep retrievable records of what it sends, and run a toll-free line staffed by a pharmacist with access to patient records at least six days and 40 hours a week, with that number printed on every container label. Other states run their own versions of nonresident registration. A telehealth peptide offer that cannot name the dispensing pharmacy, or whose product arrives without a pharmacy label and a patient name, does not look like the 503A model the statute describes, which requires a prescription for an identified individual patient.
The video call is the most visible part of a telehealth peptide offer and the least regulated. The molecule and the pharmacy carry the legal weight.
Has FDA gone after telehealth companies selling peptides?
FDA's 2026 enforcement has followed the marketing, not the video call. According to pharmaphorum, in March 2026 the agency sent 30 letters to companies that were mainly telehealth firms selling compounded versions of GLP-1 drugs. On 24 August 2026 it sent warning letters to five online vendors selling semaglutide, tirzepatide, retatrutide and other peptides labelled "for research purposes only", stating that evidence from their websites showed the products were intended as drugs for human use. The earlier Ozemback piece on whether it is illegal to sell research peptides walks through those letters and the 2026 criminal cases. None of the actions we found turned on whether a consultation happened by video. They turned on what was sold and what was claimed about it.
Isn't the state-by-state patchwork the bigger risk?
The strongest counterargument is that state law is where telehealth practices actually get disciplined, and that is fair. Licensing boards act against prescribers who treat patients in states where they hold no license, and rules on what counts as an adequate evaluation differ: Florida's statute, for example, says a provider who conducts an evaluation sufficient to diagnose and treat need not perform a physical examination first, and other states word their standard differently. Controlled-substance rules also vary by state on top of the federal floor. For the prescriber, the patchwork is the main compliance burden. For the patient asking whether a peptide offer is legal, though, federal status decides more. A perfectly licensed prescriber in the right state still cannot make an unlisted peptide compoundable under 503A.
So, can you get peptides through telehealth?
Legally, yes, within limits that have little to do with the screen. An FDA-approved peptide drug can be prescribed after a video visit by a prescriber licensed or registered in the patient's state and dispensed by a pharmacy licensed to ship there. A compounded peptide is lawful only if its ingredient fits one of the three 503A routes, and as of 28 October 2026 BPC-157, KPV, TB-500 and MOTS-c do not, whatever the July panel voted. The DEA deadline of 31 December 2026 matters for testosterone and other controlled substances, not for most peptides. Our view is that the telehealth framing flatters the sellers: it makes the legal question sound procedural when it is mostly about the molecule. We will update the tracker the day the Federal Register says otherwise.
Sources
- Drug Enforcement Administration and HHS, Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, Federal Register document 2025-24123, 31 December 2025. www.federalregister.gov
- US Food and Drug Administration, Pharmacy Compounding Advisory Committee; Notice of Meeting; Request for Comments on Bulk Drug Substances Nominated for the Section 503A List, Federal Register document 2026-07361, 16 April 2026. www.federalregister.gov
- 21 U.S.C. 353a, Pharmacy compounding (section 503A of the FD&C Act), Cornell Legal Information Institute. www.law.cornell.edu
- 21 U.S.C. 829, Prescriptions, including subsection (e) on controlled substances dispensed by means of the Internet (Ryan Haight Act), Cornell Legal Information Institute. www.law.cornell.edu
- Drug Enforcement Administration, Diversion Control Division, Controlled Substances in Alphabetical Order (testosterone, Schedule III). www.deadiversion.usdoj.gov
- Interstate Medical Licensure Compact Commission, member map and statistics, updated 5 October 2026 (information as of 30 September 2026). www.imlcc.com
- Florida Statutes, section 456.47, Use of telehealth to provide services. www.leg.state.fl.us
- Florida Statutes, section 465.0156, Registration of nonresident pharmacies. www.leg.state.fl.us
- pharmaphorum, FDA issues warning letters to five unapproved GLP-1 websites, 2 September 2026. pharmaphorum.com
